Wright Bonilla Quoted on DOJ Brief
05 November 2010
BNA’s Patent, Trademark & Copyright Journal
Foley Partner Jacqueline Wright Bonilla was quoted in an article that appeared in BNA’s Patent, Trademark & Copyright Journal on November 5, 2010 titled “DOJ’s ‘Questionable Reinterpretation’ of DNA Patentability Disappoints Patent Community.” Wright Bonilla discusses the patent community’s backlash against a brief filed by the U.S. Department of Justice as a friend of the court in the Myriad case on the patentability of genetic materials. She cautions against an overreaction to the DOJ’s brief, stating that Myriad’s composition claims directed to cDNA are patent eligible. She adds that the DOJ brief asserts this patent eligibility and meets the threshold of Section 101 of the Patent Act.
Related News
06 February 2025
In the News
Vanessa Miller Assesses Panama Canal Discourse
Foley & Lardner LLP partner Vanessa Miller commented in SupplyChainBrain article, "The Fight for Control of the Panama Canal," lending important context to the recent headlines over the important waterway.
06 February 2025
In the News
Gregory Husisian Weighs in on Suspension of De Minimis Trade Exemption
Foley & Lardner LLP partner Gregory Husisian offered context on President Trump's recent trade actions on China in The Wall Street Journal article, "Why Trump Is Closing a Trade Exemption for China."
04 February 2025
In the News
Andrew Wronski on Tariff Fluidity – 'Keep on top of the issues'
Foley & Lardner LLP partner Andrew Wronski assessed the evolving shift in U.S. trade policy in the Milwaukee Business Journal article, "Trump tariffs won't disappear — so how should Wisconsin businesses prepare?"